Definitions and Nomenclature of Neonatal Sepsis
· Probable sepsis: Is clinical and laboratory findings consistent with bacterial infection
without a positive culture.
· Clinical sepsis: When the screen and blood/cerebrospinal fluid (CSF) culture is negative, but there is a suggestive history with a high clinical suspicion.
· Culture proven or definitive sepsis: Culture positive sepsis.
· Neonatal sepsis: Best defined as presence of systemic features associated with pure growth of bacteria from one or more sites.
· At risk (ruling out sepsis): Often we “suspect” sepsis based on risk factors and clinical features, but the clinical course (rapid recovery within few hours) and “screening tests” are not suggestive; we should not label these as “suspected sepsis”. They are more like “rule out sepsis”.
Routes of Transmission
· Vertical transmission: This transmission is in utero, either hematogenous or through amniotic fluid or during birth. The symptoms usually manifest within the first 72 hours of life.
· Horizontal transmission: These are hospital-acquired infections, majority being lateonset sepsis (>72 hours of life). However, breach in asepsis during resuscitation, immediately after delivery, is also horizontal transmission, but the symptoms may manifest within the first 72 hours of life.
Approach to Management of Neonatal Sepsis
Perinatal Risk Factors
· Rupture of membranes > 24 hours
· Spontaneous preterm labor
· Chorioamnionitis (intra-amniotic infection)
· Prolonged labor
· Unclean per vaginal examinations
· Perinatal asphyxia
Extreme Risk Factors
· Rupture of membranes > 72 hours
· Chorioamnionitis (intra-amniotic infection)
· Foul smelling liquor
Definition of Intra-amniotic Infection Or Inflammation Or Both (Triple I) Maternal fever: Maternal oral temperature ≥ 39°C on any one occasion. If oral temperature is 38 (100.4) to 38.9 (102°F), repeat after 30 minutes, if repeat value remains at least 38°C (100.4) it is defined as fever
Suspected triple I: Fever without a clear source plus any of: (1) baseline fetal tachycardia (>160 bpm for >10 minutes)
Maternal total leukocyte count (TLC) > 15,000/cmm in absence of corticosteroids Definite purulent fluid from cervical os
*Confirmed triple I: All the above plus laboratory findings such as:
· Positive amniotic fluid Gram stain/culture
· Histopathological evidence of infection or inflammation or both in placenta
Management
· It is not possible to recommend a single antibiotic policy for use in all newborn units.
· It should be based on local culture and sensitivity data and profile of organisms for last 6-12 months. If not available, use data from nearby units or National Neonatal Perinatal Database (NNPD).
· Individual antibiotics and rational combinations of antibiotics must be evaluated for the percentage of organisms that they cover. The simplest and cheapest rational combination of antibiotics must be selected for each line
•• First line: Must cover approximately 75–80% of isolates
•• Second line: Must cover approximately 90–95% of isolates
•• Third line: Must cover approximately 95–100% of isolates
· Initial combination should cover both gram-negative and gram-positive organisms. One should use the lowest generation antibiotic combination which would cover about 70% of organisms. This is to ensure you have something to fall back on.
· Avoid cephalosporins as first-line antibiotics—proven harm [high risk of extended- spectrum beta-lactamases (ESBL) organisms, increased Candida infections, necrotizing enterocolitis (NEC), and mortality]—units who do not use have shown multiple benefits.
· Have a written unit/departmental/institutional antibiotic policy and practice antibiotic stewardship (reasons for starting the antibiotics, review the plan for antibiotics at 48 hours and again at 5 days based on culture reports and clinical course, have an exit plan, do not use reserve drugs without consultation)
A broad guide to initial antibiotics is mentioned below:
I. Septicemia or Pneumonia Birth weight < 2 kg
Antibiotic | Each dose | Frequency | Route | Duration (Days) | |
0–14 days age | >14 days age | ||||
Injection ampicillin* or | 50 mg/kg/dose | 12 hourly | 8 hourly | IV | 7–10 |
Injection cloxacillin# | 50 mg/kg/ dose | 12 hourly | 8 hourly | IV | 7–10 |
AND |
|
|
|
|
|
Injection gentamicin | 5 mg/kg/dose | 24 hourly | 24 hourly | IV | 7–10 |
Birth weight ≥ 2 kg |
|
| |||
Antibiotic | Each dose | Frequency | Route | Duration (Days) | |
0–7days age | >7 days age | ||||
Injection ampicillin* or | 50 mg/kg/dose | 12 hourly | 8 hourly | IV | 7–10 |
Injection cloxacillin# | 50 mg/kg/ dose | 12 hourly | 8 hourly | IV | 7–10 |
AND |
|
|
|
|
|
Injection gentamicin | 5 mg/kg/dose | 24 hourly | 24 hourly | IV | 7–10 |
II. Septicemia Second-Line Drugs Birth weight < 2 kg
Antibiotic | Each dose | Frequency | Route | Duration (Days) | |
0–14 days age | >14 days age | ||||
Injection piperacillin# |
|
|
|
|
|
Tazobactam*** | 50 mg/kg/dose | 12 hourly | 8 hourly | IV | 7–10 | |||
Injection amikacin** | 15 mg/kg/ dose | 24 hourly | 24 hourly | IV | 7–10 | |||
Birth weight ≥ 2 |
kg |
|
|
| ||||
Antibiotic | Each dose | Frequency | Route | Duration (Days) | ||||
0–7 days age | >7 days age | |||||||
Injection piperacillin# |
|
|
|
|
| |||
Tazobactam*** | 50 mg/kg/dose | 12 hourly | 8 hourly | IV | 7–10 | |||
Injection amikacin** | 15 mg/kg/ dose | 24 hourly | 24 hourly | IV | 7–10 | |||
III. Meningitis (for Confirmed Meningitis) Birth weight < 2 kg |
|
| ||||||
Antibiotic | Each dose | Frequency | Route | Duration (Weeks) | ||||
0–7 days age | >7 days age | |||||||
Injection cefotaxime* | 50 mg/kg/dose | 12 hourly | 8 hourly | IV | 3 | |||
Injection amikacin** | 15 mg/kg/ dose | 24 hourly | 24 hourly | IV | 3 | |||
Birth weight ≥ 2 |
kg |
|
| |||||
Antibiotic | Each dose | Frequency | Route | Duration (Weeks) | ||||
0–7 days age | >7 days age | |||||||
Injection cefotaxime* | 50 mg/kg/dose | 8 hourly | 6 hourly | IV | 3 | |||
Injection amikacin** | 15 mg/kg/ dose | 24 hourly | 24 hourly | IV | 3 | |||
IV. Meningitis—Second-line Drugs |
|
| ||||||
Antibiotic | Each dose | Frequency | Rout e | Duration (Weeks) |
| |||
0–7 days age | >7 days age | |||||||
Injection meropenem**** | 40 mg/kg/dose | 8 hourly | 8 hourly | IV | 3 |
| ||
Injection amikacin** | 15 mg/kg/ dose | 24 hourly | 24 hourly | IV | 3 |
| ||
# Start if pustules/umbilical sepsis.
* Infuse as an IV infusion using syringe infusion pump over 30 minutes or longer. Use a concentration not >100 mg/mL for infusion.
** Infuse as an IV infusion using syringe infusion pump over 30 minutes or longer. Use a concentration not >5 mg/mL for infusion.
*** Infuse as an IV infusion using syringe infusion pump over 30 minutes or longer. Use a concentration not >50 mg/mL for infusion.
**** Infuse as an IV infusion using syringe infusion pump over 30 minutes or longer.
Points to Remember
· As neonatal sepsis is a dynamic, complex, and heterogeneous condition, intense monitoring (subjective and objective) of the baby is warranted. A repeat sepsis screen within 12 hours may be adopted if initial screen is negative and suspicion of sepsis is strong.
· Process of taking blood culture: Take all aseptic barrier precaution [local disinfection of site with 70% alcohol, povidone iodine (avoid in extremely low birth weight), then alcohol), 1 mL of blood to be put containing at least 5 mL of broth for culture, take blood from fresh puncture site (preferably from freshly inserted intravenous cannula.
Further Reading
· Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health. 2016;4(10):e752-60.
· Leistner R, Piening B, Gastmeier P, Geffers C, Schwab F. Nosocomial infections in very low birth weight neonates in Germany: current data from the National Surveillance System NEO-KISS. Klin Padiatr. 2013;225:75-80.
· National Health Mission. Facility based newborn care guidelines. [online] Available from http://www.nhm.gov.in/index1.php?lang=1&level=3&sublinkid=1182&lid=364. [Last accessed December, 2022].
· National Neonatal Perinatal Database. Report 2002–2003. [online] Available from https://www.newbornwhocc.org/pdf/nnpd_report_2002-03.PDF. [Last accessed December, 2022].
· Sundaram V, Kumar P, Dutta S, Mukhopadhyay K, Ray P, Gautam V, et al. Blood culture confirmed bacterial sepsis in neonates in a North Indian tertiary care center: changes over the last decade. Jpn J Infect Dis. 2009;62:46-50.
· Tiskumara R, Fakharee SH, Liu CQ, Nuntnarumit P, Lui KM, Hammoud M, et al. Neonatal infections in Asia. Arch Dis Child Fetal Neonatal Ed. 2009;94:F144-8.
· Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed. 2011;96:F9-14.
References
- Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health. 2016;4(10):e752-60.
- Leistner R, Piening B, Gastmeier P, Geffers C, Schwab F. Nosocomial infections in very low birth weight neonates in Germany: current data from the National Surveillance System NEO-KISS. Klin Padiatr. 2013;225:75-80.
- National Health Mission. Facility based newborn care guidelines. [online] Available from http://www.nhm.gov.in/index1.php?lang=1&level=3&sublinkid=1182&lid=364. [Last accessed December, 2022].
- National Neonatal Perinatal Database. Report 2002–2003. [online] Available from https://www.newbornwhocc.org/pdf/nnpd_report_2002-03.PDF. [Last accessed December, 2022].
- Sundaram V, Kumar P, Dutta S, Mukhopadhyay K, Ray P, Gautam V, et al. Blood culture confirmed bacterial sepsis in neonates in a North Indian tertiary care center: changes over the last decade. Jpn J Infect Dis. 2009;62:46-50.
- Tiskumara R, Fakharee SH, Liu CQ, Nuntnarumit P, Lui KM, Hammoud M, et al. Neonatal infections in Asia. Arch Dis Child Fetal Neonatal Ed. 2009;94:F144-8.
- Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed. 2011;96:F9-14.